Depression treatment for Boynton Beach — the full escalation pathway, 12 minutes away.

RECO Integrated Psychiatry treats major depressive disorder from a Delray Beach office twelve minutes south of Boynton Beach. Every plan is anchored to a DSM-5-TR diagnosis, a baseline PHQ-9, and a defined algorithm for adequate SSRI or SNRI trials, augmentation with aripiprazole, lithium, or T3, and interventional escalation to TMS or Spravato when pharmacology alone does not remit the depression. Escalation is named at trial two, not trial four, keeping Renaissance Commons residents off a year of subtherapeutic care.

Boynton Beach sits seven miles north of the RECO Integrated Psychiatry office in Delray Beach, connected by a straight run down Federal Highway that clears in about twelve minutes outside rush hour. For adults living in Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, or Briny Breezes, that drive is shorter than a typical trip to the supermarket — short enough that specialist-run depression treatment can be built into an existing work week rather than lifted out of it. The clinical model below describes how RECO evaluates and treats major depressive disorder, from a first SSRI trial through the full interventional escalation pathway.

The diagnostic questions primary care doesn’t ask

Before “depression” is treated as depression, the initial psychiatric evaluation is structured to rule out the illnesses that mimic it. Bipolar spectrum disorder is the most consequential miss: antidepressant monotherapy in unrecognized bipolar II or cyclothymia can induce mixed states, agitation, and rapid cycling, and it is the reason a patient who has “tried four antidepressants and none of them worked” often has an unrecognized mood disorder rather than treatment-resistant unipolar depression. RECO screens with the MDQ and HCL-32 and takes a structured mood history that specifically asks about hypomanic periods disguised as productivity spikes, irritability, or reduced sleep need.

Substance use, thyroid dysfunction, chronic sleep deprivation (including untreated obstructive sleep apnea), and undertreated OCD or PTSD all present with the phenomenology of a major depressive episode. Layering an SSRI onto an untreated primary anxiety disorder or a subthreshold bipolar picture rarely produces remission; treating the underlying diagnosis usually does. Intake includes TSH, a substance use screen, YBOCS or PCL-5 when the history warrants, and a baseline PHQ-9 and GAD-7 to anchor every subsequent response measurement.

First-line pharmacotherapy done well

For a straightforward first episode of major depressive disorder, first-line pharmacotherapy is an SSRI — sertraline, escitalopram, or fluoxetine — or an SNRI such as venlafaxine XR or duloxetine when comorbid anxiety, chronic pain, or vasomotor symptoms tilt the calculus. Bupropion is the reasonable first choice when sexual side effects, weight gain, or SSRI-induced fatigue would predictably derail adherence. Mirtazapine earns its place in insomnia-predominant or anorexic presentations where a sedating, appetite-restoring agent is the shorter path to functional recovery.

A defensible trial has three parts: a starting dose that is not therapeutic (sertraline 25-50 mg, escitalopram 5-10 mg), titration to a therapeutic dose within two to four weeks, and a full six to eight weeks at that dose before response is judged. This matters beyond clinical outcomes. Insurance coverage for later escalation to TMS or Spravato requires documented adequate dose and adequate duration, which is exactly the record that hurried or fragmented treatment histories fail to produce. Every trial at RECO is dosed, dated, and measured with a repeat PHQ-9, so the paper trail is intact if escalation becomes necessary.

Augmentation and switching after partial response

At six to eight weeks the PHQ-9 tells the story. A greater than fifty percent reduction with residual symptoms is a partial response, and partial responders are augmented rather than switched — discarding a partially working antidepressant to start over rarely improves the trajectory. First-line augmentation options with the strongest evidence base are aripiprazole (2-15 mg), lithium titrated to an augmentation level of 0.4-0.8 mEq/L, and liothyronine (T3) 25-50 mcg. Quetiapine XR and olanzapine have evidence as well, weighed against their metabolic burden.

Bupropion is a useful augmentation for residual anergia, anhedonia, or SSRI-induced sexual dysfunction. Buspirone augmentation has weaker efficacy data but a benign side-effect profile for comorbid generalized anxiety. Non-response — minimal PHQ-9 movement — is different, and here a cross-class switch (SSRI to SNRI, or to bupropion) has better evidence than a within-class SSRI-to-SSRI switch. The decision to augment versus switch is documented against measured symptoms.

The interventional escalation pathway

After two adequate antidepressant trials at adequate dose and duration, the patient meets DSM-5-TR criteria for treatment-resistant depression and, in most cases, meets insurer criteria for TMS and Spravato coverage. RECO names the interventional option at trial two rather than at trial four or five, because delayed escalation is one of the largest drivers of chronicity in this illness. The escalation conversation is written into the treatment plan from visit one, not improvised after a year of subtherapeutic care.

Repetitive transcranial magnetic stimulation (rTMS) delivers focal magnetic pulses over the left dorsolateral prefrontal cortex — typically 3,000 pulses per session at 120 percent of resting motor threshold, five days a week across a six-week acute course — and is the interventional option for patients who prefer a non-medication modality with no systemic side effects. Spravato (esketamine) is the REMS-monitored intranasal option where rapid response is the priority, delivered in the office with a two-hour post-dose observation. IV racemic ketamine remains available as a cash-pay option where scheduling or insurance make esketamine impractical. All three modalities are integrated with continued antidepressant management and, where indicated, evidence-based psychotherapy (CBT, behavioral activation, or ACT) rather than delivered as stand-alone procedures.

What to expect on your first visit

The initial evaluation runs sixty to ninety minutes with a psychiatrist and is a structured diagnostic interview, not a screening. Expect the MDQ or HCL-32 to rule out bipolar spectrum, the PHQ-9 to anchor baseline severity, the GAD-7 for comorbid anxiety, plus ASRS, YBOCS, or PCL-5 when the history warrants ADHD, OCD, or trauma screening. A full prior-trial history is reconstructed — drug, dose, duration, response, side effects — because that record determines what comes next.

You leave with a written DSM-5-TR diagnosis, a specific medication or interventional recommendation, a follow-up cadence (usually two to four weeks during titration), and a measurement plan. If a prior partial response is on the chart, the augmentation plan is spelled out at that visit. If two adequate trials are already documented, the TMS or Spravato conversation happens on visit one.

Insurance and admissions from Boynton Beach

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and most Blue Cross Blue Shield plans, which covers the majority of commercial insurance carried by Palm Beach County residents. TMS and Spravato coverage typically requires documentation of two failed adequate antidepressant trials; the admissions team pulls records from prior prescribers so the prior authorization is not blocked by missing paperwork at the pharmacy stage.

Telepsychiatry is available for follow-up visits after the initial in-person evaluation is complete, which for most Boynton Beach patients means one twelve-minute drive south to Delray for intake and then a rotating mix of in-person and video follow-ups scheduled around work. Same-week initial appointments are typical outside the December holiday window.

Serving residents of: Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, Briny Breezes.